Recurrent Malignant Melanoma Eyelid -A Case Report and Review of Literature
Published: 2023-05-10
Page: 85-89
Issue: 2023 - Volume 6 [Issue 1]
Lavanya K. Uthappa
Radiation Oncology, Vydehi Institute of Medical Sciences and Research Centre, Karnataka, India.
Geeta S. Narayan
Radiation Oncology, Vydehi Institute of Medical Sciences and Research Centre, Karnataka, India.
Kiran Kumar B. R. *
Radiation Oncology, Vydehi Institute of Medical Sciences and Research Centre, Karnataka, India.
*Author to whom correspondence should be addressed.
Abstract
Malignant Melanoma of the eyelid skin arises from the abnormal proliferation of melanocytes. It is a rare condition that accounts for < 1% of all melanomas. They are usually a result of DNA damage from exposure to UVB (290-320). Other common risk factors include Fair skin, red/blond hair, high-density freckling, light eyes (green/ hazel/blue), family history of melanoma or dysplastic nevi, immunosuppression (congenital or acquired), UVA (tanning beds, PUVA therapy). Mutations in CDKN2A, CDK4, XP, BRCA2 genes occurs in 10% of the melanoma.1 Lower eyelid is the most common location of the eyelid melanoma, where it is approximately 2.6 times more likely to occur than the upper eyelid. Here we present a rare case of recurrent eyelid melanoma in a 62-year-old lady.
Keywords: Nevi, malignant melanoma, metastasis, upper eyelid, radiotherapy
How to Cite
Downloads
References
Chang AE, Karnell LH, Menck HR. The national cancer data base report on cutaneous and noncutaneous melanoma: A summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998; 83:1664–1678.
American Cancer Society—Melanoma; 2017.Available:http://old.cancer.org/cancer/analcancer/ detailed guide/anal-cancer-what-is-anal-cancer
Ogawa T, Nakayama B, Hasegawa Y, et al. Treatment of malignant melanoma of the lower eyelid using anterolateral thigh flap. Auris Nasus Larynx. 2000;27:79–82.
Foti PV, Travali M, Farina R, Palmucci S, Spatola C, Liardo RLE, Milazzotto R, Raffaele L, Salamone V, Caltabiano R, et al. Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging—Part II: Treatment indications and complications. Insights Into Imaging. 2021;12:67.
Sarici AM, Pazarli H. Gamma-knife-based stereotactic radiosurgery for medium- and large-sized posterior uveal melanoma. Graefe’s Arch. Clin. Exp. Ophthalmol. 2012;251:285–294.
Verma V, Mehta M. Clinical outcomes of proton radiotherapy for uveal melanoma. Clin. Oncol. 2016;28:e17–e27..
Jampol LM, Moy CS, Murray TG, Reynolds SM, Albert DM, Schachat AP, Diddie KR, Engstrom RE Jr, Finger PT, Hovland KR, Joffe L, Olsen KR, Wells CG. Collaborative Ocular Melanoma Study Group (COMS Group): The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, IV: Local treatment failure and enucleation in the first 5 years after brachytherapy: COMS report No. 19. Ophthalmology. 2002;109:2197-2206.
Quivey JM, Char DH, Philips TL, Weaver KA, Castro JR, Kroll SM. High intensity 125-iodine (125I) plaque treatment of uveal melanoma. Int J Radiat Oncol Biol Phys. 1993;26:613-618.
Shields CL, Cater J, Shields JA, Chao A, Krema H, Materin M, Brady LW: Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: Tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol 2002;120: 933-940.
Char DH, Kroll S, Phllips TL, Quivey JM: Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy. Ophthalmology 2002; 109:1850-1854.
Gallie BL, Simpson R, Saakyan S, Amiryan A, Valskiy V, Finger PT, Chin KJ, Semenova E, Seregard S, Fili M, Wilson M, Haik B, Caminal JM, Català J, Gutierrez C, Pelayes DE, Folgar AM, Jager MJ, Dogrusöz M, Luyten GPM, Singh A, SchachatAP, Suzuki S, Aihara Y. The ophthalmic oncology task force: Local recurrence significantly increases the risk of metastatic uveal melanoma. Ophthalmology. 2016;123:86-91.
Wolff K, Goldsmith L, Katz S, et al. Fitzpatrick’s Dermatology in General Medicine. 7th ed. New York, NY: McGraw-Hill. 2008;1134.
Clark WH Jr, Mihm MC, Jr. Lentigo maligna and lentigo-maligna melanoma. Am J Pathol. 1969;55(1):39–67.
Chang AE, Karnell LH, Menck HR. The national cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998; 83(8):1664–1678.
Hajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V. Primary mucosal melanomas: A comprehensive review. Int J Clin Exp Pathol. 2012;5(8):739–753.
Available:www.aad.org
Cascinelli N, Bombardieri E, Bufalino R, et al. Sentinel and nonsentinel node status in Stage IB and II melanoma patients: Two-step prognostic indicators of survival. J Clin Oncol. 2006;24(27): 4464–4471.
Lee JH, Essner R, Torisu-Itakura H, Wanek L, et al. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol. 2004;22(18):3677–3684.
Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–530.
obert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–39.
Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–1888.
Hendrickx A, Cozzio A, Plasswilm L, et al. Radiotherapy for lentigo maligna and lentigo maligna melanoma – A systematic review. Radiat Oncol. 2020;15:174. Available:https://doi.org/10.1186/s13014-020-01615-2
Fogarty GB, Hong A, Scolyer RA, Lin E, Haydu L, Guitera P, Thompson J.Br J Dermatol. 2014;170(1):52-8.
Cascinelli N, Bombardieri E, Bufalino R, et al. Sentinel and nonsentinel node status in Stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol. 2006;24(27):4464–4471.
Burmeister BH, Mark Smithers B, Burmeister E, et al. A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma: Trans-Tasman Radiation Oncology Group (TROG) Study 96.06. Radiother Oncol. 2006;81(2):136–142.
Brady MS. Adjuvant radiation for patients with melanoma. Lancet Oncol. 2015;16(9): 1003–1004.